AI Article Synopsis

  • The ICH Q1 guidelines establish basic standards for photostability testing of pharmaceuticals, focusing on manufacturing and storage, but do not address conditions during or after drug administration.
  • There is a lack of guidance for additional testing that could enhance safety and effectiveness during the clinical use of photosensitive drugs.
  • The commentary proposes a systematic approach using "worst case" photoexposure scenarios and existing ICH light sources to aid pharmaceutical manufacturers and pharmacists in safely using these products.

Article Abstract

Basic guidance on the photostability testing of pharmaceuticals, designed to cover manufacturing and storage over shelf life, has long been established within ICH Q1(ICH,B(10) , but the guideline does not cover the photostability of drugs during or after administration (i.e., under conditions of use). To date, there has been a paucity of guidance covering the additional testing that would be of value during the clinical preparation and use of products. This commentary suggests a systematic approach, based on realistic "worst case" photoexposure scenarios and the existing ICH Option 1 and 2 light sources, to provide valuable data to pharmaceutical manufacturers and compounding pharmacists for the safe and effective use of photosensitive injection products.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jps.23717DOI Listing

Publication Analysis

Top Keywords

guidance photostability
8
photostability testing
8
implications in-use
4
photostability
4
in-use photostability
4
photostability proposed
4
proposed guidance
4
testing labeling
4
labeling support
4
support administration
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!